CLINICAL RESEARCH: ACUTE CORONARY SYNDROME
Enhanced T-Helper-1 Lymphocyte Activation Patterns in Acute Coronary Syndromes
Heiko Methe, MD*, ,*,
Stefan Brunner*,
Daniela Wiegand*,
Michael Nabauer, MD*,
Joerg Koglin, MD* and
Elazer R. Edelman, MD, PhD
* Department of Cardiology, University Hospital Grosshadern, Ludwig-Maximilians-University, Munich, Germany
Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, and the Cardiovascular Division, Department of Internal Medicine, Brigham and Womens Hospital, Boston, Massachusetts
Manuscript received November 12, 2004;
revised manuscript received March 2, 2005,
accepted March 10, 2005.
* Reprint requests and correspondence: Dr. Heiko Methe, Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, 77 Massachusetts Avenue, Building 56-322, Cambridge, Massachusetts 02139. (Email: hmethe{at}mit.edu).
OBJECTIVES: We sought to determine whether different stages of coronary artery disease (CAD) are associated with distinct differentiation patterns of activated T cells.
BACKGROUND: Atherosclerosis is an inflammatory disease. However, little is known about specific inflammatory cell activation in atherosclerosis, for example, the T-helper (Th)1/Th2-balance.
METHODS: We studied 18 patients with stable angina (SA), 28 patients with acute coronary syndrome (ACS) (16 with unstable angina pectoris and 12 with ST-segment elevation myocardial infarction), 19 patients with unheralded myocardial infarction (UH), and 16 control patients. Cytokine patterns and transcription factor signaling pathways of circulating T cells were characterized using reverse transcription polymerase chain reaction and flow cytometry.
RESULTS: Although interferon (IFN)- +/CD3+ T cells were 2-fold greater in patients with SA or UH than in control subjects, there was a massive expansion of Th1 cells in patients with ACS (p < 0.001). This increase was paralleled by significantly increased mRNA transcript levels for signal-transducer-and-activator-4 (ACS 1.17 ± 0.14 relative units [RU]; control patients 0.44 ± 0.09 RU; SA 0.67 ± 0.12 RU; UH 0.61 ± 0.17 RU), interleukin-2 (ACS 1.55 ± 0.51 RU; control patients 0.21 ± 0.09 RU; SA 0.54 ± 0.18 RU; UH 0.45 ± 0.16 RU), and IFN- in ACS (1.27 ± 0.39 RU; control patients 0.35 ± 0.09 RU; SA 0.58 ± 0.11 RU; UH 0.53 ± 0.24 RU; p < 0.002). Th2 and Th0 cells were not different across patient subsets. The burden of CAD was identical between SA (1.4 ± 0.2 diseased vessels, 68 ± 13% diameter stenosis) and ACS (1.4 ± 0.2 diseased vessels, 64 ± 17% diameter stenosis) but significantly greater in patients with UH (2.5 ± 0.5 diseased vessels, 95 ± 7% diameter stenosis; p < 0.05).
CONCLUSIONS: Patients with UH have a greater burden of obstructive CAD than SA but no greater T-cell activation. Patients with ACS have the same extent of CAD than SA but significantly greater activation of Th1 cells that may contribute to the increasing instability. Differences in circulating Th1 cells might indicate different pathogenic components, leading to ACS and UH.
|
Abbreviations and Acronyms
| | ACS = acute coronary syndrome | | CAD = coronary artery disease | | CK = creatine kinase | | CRP = C-reactive protein | | FACS = fluorescence-activated cell sorter | | IFN = interferon | | IL = interleukin | | PBS = phosphate-buffered saline | | SA = stable angina pectoris | | STAT = signal transducer and activator of transcription | | STEMI = ST-segment elevation myocardial infarction | | Th = T-helper | | UA = unstable angina pectoris | | UH = unheralded myocardial infarction |
|
This article has been cited by other articles:

|
 |

|
 |
 
I. T. Padol and R. H. Hunt
Association of myocardial infarctions with COX-2 inhibition may be related to immunomodulation towards a Th1 response resulting in atheromatous plaque instability: an evidence-based interpretation
Rheumatology,
September 24, 2009;
(2009)
kep225v1.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Ammirati, A.-C. Vermi, D. Cianflone, M. Banfi, C. Foglieni, C. Godino, F. Airoldi, L. A. Ferri, C. L. Gorman, A. A. Manfredi, et al.
Expansion of T-Cell Receptor {zeta}dim Effector T Cells in Acute Coronary Syndromes
Arterioscler Thromb Vasc Biol,
December 1, 2008;
28(12):
2305 - 2311.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Naito, T. Anzai, Y. Sugano, Y. Maekawa, T. Kohno, T. Yoshikawa, K. Matsuno, and S. Ogawa
Differential Effects of GM-CSF and G-CSF on Infiltration of Dendritic Cells during Early Left Ventricular Remodeling after Myocardial Infarction
J. Immunol.,
October 15, 2008;
181(8):
5691 - 5701.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Methe and M. Weis
Atherogenesis and inflammation--was Virchow right?
Nephrol. Dial. Transplant.,
July 1, 2007;
22(7):
1823 - 1827.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
K. Shimada, J. K. Park, and H. Daida
T helper 1/T helper 2 balance and HMG-CoA reductase inhibitors in acute coronary syndrome: statins as immunomodulatory agents?
Eur. Heart J.,
December 2, 2006;
27(24):
2916 - 2918.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. M Carter
Inflammation, thrombosis and acute coronary syndromes
Diabetes and Vascular Disease Research,
October 1, 2005;
2(3):
113 - 121.
[Abstract]
[PDF]
|
 |
|
|